{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Multitask Learning\n",
    "\n",
    "Use a single shared representation to predict gender and phase 2"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load Embeddings and Abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "%store -r embeddings_info\n",
    "\n",
    "abstracts = embeddings_info['abstracts']\n",
    "abstracts_padded = embeddings_info['abstracts_padded']\n",
    "embeddings = embeddings_info['embeddings']\n",
    "word_dim = embeddings_info['word_dim']\n",
    "word2idx, idx2word = embeddings_info['word2idx'], embeddings_info['idx2word']\n",
    "maxlen = embeddings_info['maxlen']\n",
    "vocab_size = embeddings_info['vocab_size']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Load Labels"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "%store -r pruned_dataset binarized_dataset\n",
    "\n",
    "ys = np.array(binarized_dataset).T\n",
    "\n",
    "from support import classinfo_generator\n",
    "\n",
    "labels = pruned_dataset.columns.tolist()\n",
    "class_info = list(classinfo_generator(pruned_dataset))\n",
    "class_names, class_sizes = zip(*class_info)\n",
    "class_names = {label: classes for label, classes in zip(labels, class_names)}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Train - Validation Split"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "from sklearn.cross_validation import KFold\n",
    "\n",
    "fold = KFold(len(abstracts_padded), n_folds=5, shuffle=True)\n",
    "p = iter(fold)\n",
    "\n",
    "train_idxs, val_idxs = next(p)\n",
    "val_idxs = train_idxs # HARD-CODE VALIDATION SET TO TRAINING SET FOR NOW!!!\n",
    "\n",
    "X_train, ys_train = abstracts_padded[train_idxs], ys[:, train_idxs]\n",
    "X_val, ys_val = abstracts_padded[val_idxs], ys[:, val_idxs]\n",
    "\n",
    "num_train, num_val = len(X_train), len(X_val)\n",
    "\n",
    "val_dict = {label: y_row for label, y_row in zip(labels, ys_val)}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Hyperparameters"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "nb_filter = 20\n",
    "filter_length = 2\n",
    "hidden_dims = 32\n",
    "nb_epoch = 35\n",
    "batch_size = 10"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Define Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [],
   "source": [
    "from keras.models import Graph\n",
    "from keras.layers.core import Dense, Dropout, Activation, Flatten\n",
    "from keras.layers.embeddings import Embedding\n",
    "from keras.layers.convolutional import Convolution1D, MaxPooling1D\n",
    "\n",
    "model = Graph()\n",
    "model.add_input(name='input', input_shape=[maxlen], dtype='int') # dtype='int' is 100% necessary for some reason!\n",
    "model.add_node(Embedding(input_dim=vocab_size, output_dim=word_dim, weights=[embeddings], input_length=maxlen, trainable=False),\n",
    "               name='embedding', input='input')\n",
    "model.add_node(Dropout(0.25), name='dropout1', input='embedding')\n",
    "\n",
    "model.add_node(Convolution1D(nb_filter=nb_filter,\n",
    "                             filter_length=filter_length,\n",
    "                             activation='relu'),\n",
    "              name='conv',\n",
    "              input='dropout1')\n",
    "model.add_node(MaxPooling1D(pool_length=maxlen-1), name='pool', input='conv') # non-maximum suppression\n",
    "model.add_node(Flatten(), name='flat', input='pool')\n",
    "model.add_node(Dense(hidden_dims), name='z', input='flat')\n",
    "model.add_node(Activation('relu'), name='shared', input='z')\n",
    "model.add_node(Dropout(0.25), name='dropout2', input='shared')\n",
    "\n",
    "# Fork the graph and predict probabilities for each target from shared representation\n",
    "for label, num_classes in zip(labels, class_sizes):\n",
    "    model.add_node(Dense(output_dim=num_classes, activation='softmax'), name='{}_probs'.format(label), input='dropout2')\n",
    "    model.add_output(name=label, input='{}_probs'.format(label))\n",
    "\n",
    "model.compile(optimizer='rmsprop',\n",
    "              loss={label: 'categorical_crossentropy' for label in labels}) # CE for all the targets"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Random Minibatch Generator"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "def batch_generator(ys, batch_size, balanced=True):\n",
    "    \"\"\"Yield successive batches for training\n",
    "    \n",
    "    This generator is not meant to be exhausted, but rather called by next().\n",
    "    \n",
    "    Each batch has batch_size/num_classes number of examples from each class\n",
    "    \n",
    "    \"\"\"\n",
    "    num_objectives, num_train = ys.shape\n",
    "    \n",
    "    while True:\n",
    "        yield np.random.choice(num_train, size=batch_size)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Minibatch Training"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "batch_size = num_train // 2\n",
    "\n",
    "train_batch = batch_generator(ys_train, batch_size)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[array(0.7199770212173462, dtype=float32)]\n",
      "gender accuracy: 0.6875\n",
      "phase_2 accuracy: 1.0\n",
      "[array(0.7814040184020996, dtype=float32)]\n",
      "gender accuracy: 0.6875\n",
      "phase_2 accuracy: 1.0\n",
      "[array(0.8557045459747314, dtype=float32)]\n",
      "gender accuracy: 0.75\n",
      "phase_2 accuracy: 1.0\n",
      "[array(0.4954754710197449, dtype=float32)]\n",
      "gender accuracy: 0.75\n",
      "phase_2 accuracy: 1.0\n",
      "[array(0.5447196960449219, dtype=float32)]\n",
      "gender accuracy: 0.875\n",
      "phase_2 accuracy: 1.0\n",
      "[array(0.9085276126861572, dtype=float32)]\n",
      "gender accuracy: 0.875\n",
      "phase_2 accuracy: 1.0\n",
      "[array(0.6383398771286011, dtype=float32)]\n",
      "gender accuracy: 0.9375\n",
      "phase_2 accuracy: 1.0\n",
      "[array(0.36813780665397644, dtype=float32)]\n",
      "gender accuracy: 0.9375\n",
      "phase_2 accuracy: 1.0\n",
      "[array(0.4402334690093994, dtype=float32)]\n",
      "gender accuracy: 0.9375\n",
      "phase_2 accuracy: 1.0\n",
      "[array(0.6036130785942078, dtype=float32)]\n",
      "gender accuracy: 1.0\n",
      "phase_2 accuracy: 1.0\n"
     ]
    }
   ],
   "source": [
    "from support import produce_labels\n",
    "\n",
    "for i in range(100):\n",
    "    batch_idxs = next(train_batch)\n",
    "    \n",
    "    X = X_train[batch_idxs]\n",
    "    train_dict = dict(produce_labels(labels, class_sizes, ys_train[:, batch_idxs]))\n",
    "    train_dict.update({'input': X})\n",
    "\n",
    "    train_error = model.train_on_batch(train_dict)\n",
    "\n",
    "    if not i % 10:\n",
    "        print train_error\n",
    "        \n",
    "        predictions = model.predict({'input': X_val})\n",
    "        for label, ys_pred in predictions.items():\n",
    "            print '{} accuracy:'.format(label), np.mean(ys_pred.argmax(axis=1) == val_dict[label])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Confusion Matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAARgAAAJpCAYAAAB2GC11AAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nZgwYSc0YMJKaMWAkNWPASGrGgJHUzP8BkaUHipO3coUAAAAASUVORK5CYII=\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x7fdc0dbdcf10>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from sklearn.metrics import confusion_matrix\n",
    "from support import plot_confusion_matrix\n",
    "\n",
    "predictions = model.predict({'input': X_val})\n",
    "\n",
    "fig = plt.figure(figsize=(10,10))\n",
    "plt.clf()\n",
    "\n",
    "for i, [(label, ys_pred), y_row] in enumerate(zip(predictions.items(), ys_val), start=1):\n",
    "    axes = fig.add_subplot(2, 1, i)\n",
    "    \n",
    "    cm = confusion_matrix(y_row, ys_pred.argmax(axis=1))\n",
    "    plot_confusion_matrix(cm, class_names[label])\n",
    "    \n",
    "    fig.subplots_adjust(wspace=.35, hspace=.65)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Examine Bigrams Which Filters Fire on"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "D-Cycloserine, a partial agonist at the glycine site of the N-methyl-D-aspartate receptor, has demonstrated inconsistent efficacy for negative and cognitive symptoms of schizophrenia. The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less. \n",
      "                 To assess the efficacy for negative symptoms and cognitive impairment of D-cycloserine augmentation of conventional antipsychotics in a 6-month trial. \n",
      "                 Fifty-five schizophrenia patients with prominent negative symptoms, treated with conventional antipsychotics, were randomly assigned to treatment with D-cycloserine 50 mg/day or placebo for 6 months in a double-blind, parallel group design. \n",
      "                 Twenty-six subjects completed the 6-month trial; drop-out rates did not differ between treatment groups. D-Cycloserine treatment did not differ from placebo treatment on any primary outcome measure at 8 or 24 weeks, including response of negative symptoms and performance on a cognitive battery. Serum D-cycloserine concentrations did not correlate with response of negative symptoms. \n",
      "                 D-Cycloserine did not exhibit therapeutic effects in this trial, possibly reflecting the high drop-out rate, a narrow range of therapeutic serum concentrations, a modest magnitude of therapeutic effect for the selected outcome measures, or loss of efficacy over time. Because D-cycloserine is a partial agonist with relatively low affinity for the glycine site, the magnitude of potential therapeutic effect may be smaller than that achieved by the higher-affinity full agonists, glycine and D-serine.\n",
      "\n",
      "gender Both\n",
      "phase_2 False\n",
      "\n",
      "0.190570001422 , possibly\n",
      "0.179746134367 and cognitive\n",
      "0.179746134367 and cognitive\n",
      "0.168316765647 and performance\n",
      "0.166524890278 exhibit therapeutic\n",
      "0.139667075701 , including\n",
      "0.132791538284 potential therapeutic\n",
      "0.13251256398 may be\n",
      "0.128143618429 , has\n",
      "0.122618773503 effect may\n",
      "\n",
      "0.371055330606 , treated\n",
      "0.360609691841 , including\n",
      "0.343369925395 , a\n",
      "0.343369925395 , a\n",
      "0.343369925395 , a\n",
      "0.339483219267 , has\n",
      "0.338984931233 , or\n",
      "0.337927538141 , the\n",
      "0.335936892465 , glycine\n",
      "0.311772616154 , possibly\n",
      "\n",
      "0.183345933916 in a\n",
      "0.183345933916 in a\n",
      "0.15824050427 in this\n",
      "0.132324251597 group design\n",
      "0.121132220114 and performance\n",
      "0.113213938055 cognitive battery\n",
      "0.113142339099 of therapeutic\n",
      "0.113142339099 of therapeutic\n",
      "0.112750320221 outcome measure\n",
      "0.0962789825317 using D-cycloserine\n",
      "\n",
      "0.187251041474 on a\n",
      "0.175862129112 at a\n",
      "0.170687815467 concentrations ,\n",
      "0.143897549358 , a\n",
      "0.143897549358 , a\n",
      "0.143897549358 , a\n",
      "0.133820068706 weeks ,\n",
      "0.121960036095 site ,\n",
      "0.118052422768 affinity for\n",
      "0.115080397372 measures ,\n",
      "\n",
      "0.206987134674 symptoms ,\n",
      "0.172477776704 symptoms and\n",
      "0.172477776704 symptoms and\n",
      "0.171214286382 symptoms .\n",
      "0.164142833139 measures ,\n",
      "0.159617726638 ; drop-out\n",
      "0.135029119413 rate ,\n",
      "0.129140939353 weeks ,\n",
      "0.126161566921 antipsychotics ,\n",
      "0.12253158129 trial ;\n",
      "\n",
      "0.280873137991 reflecting the\n",
      "0.278151120716 at the\n",
      "0.269696368746 symptoms of\n",
      "0.262834690317 completed the\n",
      "0.247957699101 magnitude of\n",
      "0.247957699101 magnitude of\n",
      "0.231991686505 antipsychotics in\n",
      "0.231991686505 antipsychotics in\n",
      "0.230046162175 by the\n",
      "0.224207898319 assess the\n",
      "\n",
      "0.165026876595 studies using\n",
      "0.160466217008 any primary\n",
      "0.144387180739 this trial\n",
      "0.137406665128 evidence for\n",
      "0.123221620028 strongest evidence\n",
      "0.118353644807 The strongest\n",
      "0.110928319706 potential therapeutic\n",
      "0.109981068751 To assess\n",
      "0.109240169803 site of\n",
      "0.0990996075248 higher-affinity full\n",
      "\n",
      "0.27738834011 come from\n",
      "0.256261656888 differ from\n",
      "0.0947826189931 50 mg/day\n",
      "0.0947826189931 50 mg/day\n",
      "0.0621063877612 smaller than\n",
      "0.0573295733079 over time\n",
      "0.0457828895472 to conventional\n",
      "0.0277841761988 has come\n",
      "0.0209826209615 low affinity\n",
      "0.00943921387182 achieved by\n",
      "\n",
      "0.288098119057 drop-out rate\n",
      "0.27346728957 rate ,\n",
      "0.239329223206 dose of\n",
      "0.183237086875 drop-out rates\n",
      "0.175577561792 rates did\n",
      "0.153130625894 modest magnitude\n",
      "0.130416337191 partial agonist\n",
      "0.130416337191 partial agonist\n",
      "0.0852785222479 D-cycloserine concentrations\n",
      "0.0798628797535 concentrations ,\n",
      "\n",
      "0.698275639284 or placebo\n",
      "0.652659881859 from placebo\n",
      "0.543581834401 group design\n",
      "0.387868964163 parallel group\n",
      "0.386047484734 conventional antipsychotics\n",
      "0.386047484734 conventional antipsychotics\n",
      "0.386047484734 conventional antipsychotics\n",
      "0.313136342891 ; drop-out\n",
      "0.294918292183 50 mg/day\n",
      "0.294918292183 50 mg/day\n",
      "\n",
      "0.255441978718 that achieved\n",
      "0.243857604176 has demonstrated\n",
      "0.186390893005 D-cycloserine concentrations\n",
      "0.169866600488 by the\n",
      "0.163609288071 over time\n",
      "0.16272392662 possibly reflecting\n",
      "0.1626678937 . Serum\n",
      "0.157397679715 be smaller\n",
      "0.153633251167 differ between\n",
      "0.153175707431 or loss\n",
      "\n",
      "0.454893863007 added to\n",
      "0.281246781153 than that\n",
      "0.156608986373 concentrations did\n",
      "0.120255947205 effect may\n",
      "0.109087813617 using D-cycloserine\n",
      "0.0999316499708 concentrations ,\n",
      "0.0887796544433 glycine site\n",
      "0.0887796544433 glycine site\n",
      "0.0833130313397 partial agonist\n",
      "0.0833130313397 partial agonist\n",
      "\n",
      "0.441347496218 smaller than\n",
      "0.423281208541 or less\n",
      "0.322345625911 be smaller\n",
      "0.206830140046 8 or\n",
      "0.197628237849 duration or\n",
      "0.195361230998 with relatively\n",
      "0.188584248028 with prominent\n",
      "0.168185042354 mg/day or\n",
      "0.166740139497 , or\n",
      "0.162026490761 the magnitude\n",
      "\n",
      "0.192896098765 over time\n",
      "0.191852889882 come from\n",
      "0.12873118836 a narrow\n",
      "0.104350260174 or 24\n",
      "0.0939594931398 on any\n",
      "0.0934830321508 reflecting the\n",
      "0.0898264631515 time .\n",
      "0.0842593191676 has come\n",
      "0.0832582069493 symptoms .\n",
      "0.0826419819938 inconsistent efficacy\n",
      "\n",
      "0.672276565497 , the\n",
      "0.643824963254 , has\n",
      "0.60129446695 , were\n",
      "0.597691143072 , treated\n",
      "0.583974551472 , a\n",
      "0.583974551472 , a\n",
      "0.583974551472 , a\n",
      "0.567671138766 , parallel\n",
      "0.563534505843 , or\n",
      "0.532006595359 , glycine\n",
      "\n",
      "0.241658904477 6 months\n",
      "0.22863603134 , a\n",
      "0.22863603134 , a\n",
      "0.22863603134 , a\n",
      "0.227865420802 , were\n",
      "0.223512588416 , the\n",
      "0.191941954977 , parallel\n",
      "0.191324196154 weeks duration\n",
      "0.191175080574 ; drop-out\n",
      "0.189519976216 , has\n",
      "\n",
      "0.212149144678 glycine site\n",
      "0.212149144678 glycine site\n",
      "0.168500934648 N-methyl-D-aspartate receptor\n",
      "0.147994224686 agonists ,\n",
      "0.109027150743 D-cycloserine augmentation\n",
      "0.106588128743 higher-affinity full\n",
      "0.102531646878 D-cycloserine concentrations\n",
      "0.0903676897447 agonist at\n",
      "0.0825083121774 receptor ,\n",
      "0.0690293902036 D-Cycloserine did\n",
      "\n",
      "0.215585302392 8 weeks\n",
      "0.161327148016 8 or\n",
      "0.128749138045 24 weeks\n",
      "0.108861762268 , glycine\n",
      "0.10383218724 6 months\n",
      "0.100182635911 serum concentrations\n",
      "0.0997103871582 N-methyl-D-aspartate receptor\n",
      "0.0926001032511 D-cycloserine concentrations\n",
      "0.0849445711626 , parallel\n",
      "0.0804915775338 performance on\n",
      "\n",
      "0.417725433852 battery .\n",
      "0.363723604558 design .\n",
      "0.362823782202 D-serine .\n",
      "0.344500599084 less .\n",
      "0.339130283569 schizophrenia .\n",
      "0.330427136017 groups .\n",
      "0.315605696859 trial .\n",
      "0.310114242173 8 or\n",
      "0.297354025545 time .\n",
      "0.295630808427 , or\n",
      "\n",
      "0.243316431126 ; drop-out\n",
      "0.205395385123 , parallel\n",
      "0.164976271968 and D-serine\n",
      "0.161953306576 trial ;\n",
      "0.158709335313 or placebo\n",
      "0.155372020694 mg/day added\n",
      "0.15122122116 , possibly\n",
      "0.150905990679 , the\n",
      "0.123415119011 group design\n",
      "0.117728819138 or less\n",
      "\n",
      "Patients with metastatic or recurrent Ewing's sarcoma family of tumors and alveolar rhabdomyosarcoma have <25% 5-year survival in most studies. This study administered a novel immunotherapy regimen aimed at consolidating remission in these patients. \n",
      "                 Fifty-two patients with translocation positive, recurrent, or metastatic Ewing's sarcoma family of tumors or alveolar rhabdomyosarcoma underwent prechemotherapy cell harvest via apheresis for potential receipt of immunotherapy. Following completion of standard multimodal therapy, 30 patients ultimately initiated immunotherapy and were sequentially assigned to three cohorts. All cohorts received autologous T cells, influenza vaccinations, and dendritic cells pulsed with peptides derived from tumor-specific translocation breakpoints and E7, a peptide known to bind HLA-A2. Cohort 1 received moderate-dose recombinant human interleukin-2 (rhIL-2), cohort 2 received low-dose rhIL-2, and cohort 3 did not receive rhIL-2. \n",
      "                 All immunotherapy recipients generated influenza-specific immune responses, whereas immune responses to the translocation breakpoint peptides occurred in 39%, and only 25% of HLA-A2(+) patients developed E7-specific responses. Toxicity was minimal. Intention-to-treat analysis revealed a 31% 5-year overall survival for all patients apheresed (median potential follow-up 7.3 years) with a 43% 5-year overall survival for patients initiating immunotherapy. \n",
      "                 Consolidative immunotherapy is a scientifically based and clinically practical approach for integrating immunotherapy into a multimodal regimen for chemoresponsive cancer. Patients receiving immunotherapy experienced minimal toxicity and favorable survival. The robust influenza immune responses observed suggest that postchemotherapy immune incompetence will not fundamentally limit this approach. Future studies will seek to increase efficacy by using more immunogenic antigens and more potent dendritic cells.\n",
      "\n",
      "gender Both\n",
      "phase_2 True\n",
      "\n",
      "0.275734770948 and E7\n",
      "0.2242536602 and clinically\n",
      "0.2200328281 , recurrent\n",
      "0.204502652294 or metastatic\n",
      "0.191153092505 with metastatic\n",
      "0.171442686005 and favorable\n",
      "0.169178001272 . Future\n",
      "0.155548865881 novel immunotherapy\n",
      "0.149251636011 for potential\n",
      "0.143039932048 recombinant human\n",
      "\n",
      "0.418268469542 , whereas\n",
      "0.398543516598 , cohort\n",
      "0.38528658926 , 30\n",
      "0.351361689754 , and\n",
      "0.351361689754 , and\n",
      "0.351361689754 , and\n",
      "0.343369925395 , a\n",
      "0.338984931233 , or\n",
      "0.338158445887 , recurrent\n",
      "0.32222731905 , influenza\n",
      "\n",
      "0.357256781428 practical approach\n",
      "0.297146812896 clinically practical\n",
      "0.277951338095 patients developed\n",
      "0.258413899697 for integrating\n",
      "0.240490220911 approach for\n",
      "0.240148787205 standard multimodal\n",
      "0.224826587353 incompetence will\n",
      "0.198088517553 scientifically based\n",
      "0.196911151318 approach .\n",
      "0.192033417701 integrating immunotherapy\n",
      "\n",
      "0.214974179223 revealed a\n",
      "0.210652839766 administered a\n",
      "0.169592139638 into a\n",
      "0.143897549358 , a\n",
      "0.140643063116 with a\n",
      "0.115644159091 % ,\n",
      "0.107661858727 recombinant human\n",
      "0.103333090433 is a\n",
      "0.101783020846 E7 ,\n",
      "0.101076002812 sarcoma family\n",
      "\n",
      "0.269295182291 % ,\n",
      "0.194133680452 interleukin-2 (\n",
      "0.167715920509 % 5-year\n",
      "0.167715920509 % 5-year\n",
      "0.167715920509 % 5-year\n",
      "0.160862092034 years )\n",
      "0.152834243424 recurrent ,\n",
      "0.152060896084 therapy ,\n",
      "0.145282876052 HLA-A2 (\n",
      "0.142280813817 + )\n",
      "\n",
      "0.260959990649 to the\n",
      "0.194669544198 receipt of\n",
      "0.190140384217 prechemotherapy cell\n",
      "0.168421138742 limit this\n",
      "0.153468828102 observed suggest\n",
      "0.149985937494 7.3 years\n",
      "0.138526810208 % of\n",
      "0.138024644928 responses observed\n",
      "0.137973190671 . The\n",
      "0.130087269531 Patients with\n",
      "\n",
      "0.696102490687 study administered\n",
      "0.272901395607 studies will\n",
      "0.198428363983 studies .\n",
      "0.148728353919 analysis revealed\n",
      "0.11948697736 novel immunotherapy\n",
      "0.118950871772 's sarcoma\n",
      "0.118950871772 's sarcoma\n",
      "0.118507537846 this approach\n",
      "0.10885188559 cohort 3\n",
      "0.106406658164 The robust\n",
      "\n",
      "0.234165617017 derived from\n",
      "0.0798684970791 25 %\n",
      "0.0798684970791 25 %\n",
      "0.044030870997 7.3 years\n",
      "0.0413640024631 to bind\n",
      "0.0362602984386 incompetence will\n",
      "0.0302495300838 peptides derived\n",
      "0.0229412893914 via apheresis\n",
      "0.0216867453141 limit this\n",
      "0.0214028098337 will seek\n",
      "\n",
      "0.188537614358 to increase\n",
      "0.18346005943 fundamentally limit\n",
      "0.0894224782884 Intention-to-treat analysis\n",
      "0.0783641370837 cell harvest\n",
      "0.065993673317 5-year overall\n",
      "0.065993673317 5-year overall\n",
      "0.064868507715 translocation breakpoint\n",
      "0.0604038432419 follow-up 7.3\n",
      "0.0558920289721 responses observed\n",
      "0.0555406223742 limit this\n",
      "\n",
      "0.344576082483 received moderate-dose\n",
      "0.336883052717 cohorts received\n",
      "0.318878307237 received low-dose\n",
      "0.283805699079 Patients receiving\n",
      "0.203824812141 . Intention-to-treat\n",
      "0.186013917259 patients apheresed\n",
      "0.157920844206 ( median\n",
      "0.155313132591 31 %\n",
      "0.149213308887 39 %\n",
      "0.147061217302 43 %\n",
      "\n",
      "0.77862941706 responses observed\n",
      "0.299893461875 suggest that\n",
      "0.293971271958 Following completion\n",
      "0.293651267185 peptides occurred\n",
      "0.223427595023 via apheresis\n",
      "0.200930129427 low-dose rhIL-2\n",
      "0.190935213456 peptides derived\n",
      "0.189646606052 generated influenza-specific\n",
      "0.163112171687 occurred in\n",
      "0.161403645536 underwent prechemotherapy\n",
      "\n",
      "0.365991978564 suggest that\n",
      "0.265233753922 toxicity and\n",
      "0.180653412112 Toxicity was\n",
      "0.175295770676 sarcoma family\n",
      "0.175295770676 sarcoma family\n",
      "0.170535405115 bind HLA-A2\n",
      "0.103038943024 breakpoint peptides\n",
      "0.100304542425 peptides derived\n",
      "0.0990746923678 rhabdomyosarcoma have\n",
      "0.0948030516187 potent dendritic\n",
      "\n",
      "0.57759103595 using more\n",
      "0.55821858511 and more\n",
      "0.351725434759 dendritic cells\n",
      "0.351725434759 dendritic cells\n",
      "0.297458719542 E7-specific responses\n",
      "0.281926900696 immunogenic antigens\n",
      "0.280118648558 T cells\n",
      "0.277155258984 in most\n",
      "0.276429546228 immunotherapy experienced\n",
      "0.25277275171 HLA-A2 .\n",
      "\n",
      "0.126248729415 Following completion\n",
      "0.124422670598 received low-dose\n",
      "0.116603609744 immunotherapy regimen\n",
      "0.112843198525 practical approach\n",
      "0.106547022582 multimodal regimen\n",
      "0.0987325348266 potential follow-up\n",
      "0.0968184386297 will seek\n",
      "0.0957207210808 Patients receiving\n",
      "0.0922411454689 ultimately initiated\n",
      "0.0811472851375 received moderate-dose\n",
      "\n",
      "0.855374121419 , cohort\n",
      "0.716259145931 , 30\n",
      "0.71473221836 7.3 years\n",
      "0.606253361504 , influenza\n",
      "0.60168569312 , recurrent\n",
      "0.583974551472 , a\n",
      "0.563534505843 , or\n",
      "0.55633014744 , and\n",
      "0.55633014744 , and\n",
      "0.55633014744 , and\n",
      "\n",
      "0.320552244082 , cohort\n",
      "0.289340401625 7.3 years\n",
      "0.281652246782 potential follow-up\n",
      "0.244032796351 , influenza\n",
      "0.22863603134 , a\n",
      "0.21425375703 , 30\n",
      "0.205159136603 ( median\n",
      "0.203066378945 , recurrent\n",
      "0.184329310123 , and\n",
      "0.184329310123 , and\n",
      "\n",
      "0.297990484597 peptides occurred\n",
      "0.222519248955 peptide known\n",
      "0.206208118737 peptides derived\n",
      "0.202584783758 tumor-specific translocation\n",
      "0.16272837518 cells pulsed\n",
      "0.16072869308 E7-specific responses\n",
      "0.156299512362 to bind\n",
      "0.142519879153 HLA-A2 (\n",
      "0.139682127009 recombinant human\n",
      "0.139631360357 T cells\n",
      "\n",
      "0.398444643116 harvest via\n",
      "0.345679322588 prechemotherapy cell\n",
      "0.34094066994 ( rhIL-2\n",
      "0.293402539484 T cells\n",
      "0.267899092856 dendritic cells\n",
      "0.267899092856 dendritic cells\n",
      "0.253125801031 autologous T\n",
      "0.240233756749 ( +\n",
      "0.194777635715 ( median\n",
      "0.164831908966 3 did\n",
      "\n",
      "0.450378314245 HLA-A2 .\n",
      "0.411554829767 responses .\n",
      "0.402117364744 cohorts .\n",
      "0.401040499122 cells .\n",
      "0.391503518439 immunotherapy .\n",
      "0.391503518439 immunotherapy .\n",
      "0.373399285585 rhIL-2 .\n",
      "0.355528656522 studies .\n",
      "0.314631614794 approach .\n",
      "0.295630808427 , or\n",
      "\n",
      "0.296561082339 ( +\n",
      "0.197265353307 follow-up 7.3\n",
      "0.165094792632 , influenza\n",
      "0.156392558182 or alveolar\n",
      "0.153302958266 ) with\n",
      "0.150112578984 and alveolar\n",
      "0.138652497207 The robust\n",
      "0.120368755713 . Intention-to-treat\n",
      "0.113643499706 , whereas\n",
      "0.112494280717 ( median\n",
      "\n",
      "To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with extended field irradiation in women with cervical cancer metastatic to the para-aortic nodes. \n",
      "                 Patients with carcinoma of the cervix and histologically documented para-aortic node metastases were eligible for this phase I/II trial. Chemotherapy agents were administered weekly concurrent with extended field radiation with escalating doses of paclitaxel from 30-50 mg/m(2) in each of three cohorts of three patients each. A phase II cohort was then evaluated at the selected maximum tolerated dose (MTD). \n",
      "                 The MTD was determined to be cisplatin 40 mg/m(2) (maximum dose of 70 mg) and paclitaxel 40 mg/m(2) administered weekly for six cycles concurrent with extended field radiation therapy. There were 19 evaluable patients for the phase II analysis of toxicity and efficacy. Grade three and four gastrointestinal toxicity was seen in 6 and neutropenia in 7. Radiation therapy was successfully completed in 36.8% of patients at eight weeks and in 68.4% of patients at nine weeks, with a median time to completion was 56 days. A total of 27 evaluable patients were enrolled, twelve are dead (mean survival of those deceased is 25 months), and 15 (56%) are alive, and have been followed for a mean of 48 months (range 25-68; median of 46 months). \n",
      "                 Paclitaxel and cisplatin combination chemotherapy concurrent with extended field pelvic para-aortic irradiation can be administered at the described MTD and shows a higher than previously reported disease-free survival in relation to historical data. The 56% survival to date, and 50% estimated 48 month survival, warrants validation in a larger prospective cohort. Central radiation dose reduction is being considered in the next trial to decrease late toxicity of regimen.\n",
      "\n",
      "gender Female\n",
      "phase_2 False\n",
      "\n",
      "0.297998883507 the cervix\n",
      "0.23984249972 and histologically\n",
      "0.215493684032 with cervical\n",
      "0.186490936686 decrease late\n",
      "0.184669946962 with carcinoma\n",
      "0.174237893501 , warrants\n",
      "0.161077024488 and have\n",
      "0.160143715662 and in\n",
      "0.157982168961 and efficacy\n",
      "0.153843217881 late toxicity\n",
      "\n",
      "0.351361689754 , and\n",
      "0.351361689754 , and\n",
      "0.351361689754 , and\n",
      "0.350541428964 , twelve\n",
      "0.3070194868 , with\n",
      "0.293460914609 , warrants\n",
      "0.266907001858 50 %\n",
      "0.250353441402 68.4 %\n",
      "0.233868677265 56 %\n",
      "0.233868677265 56 %\n",
      "\n",
      "0.183345933916 in a\n",
      "0.177219159716 in relation\n",
      "0.173459220724 validation in\n",
      "0.167525085746 the described\n",
      "0.12456916414 in the\n",
      "0.0984075292575 warrants validation\n",
      "0.0897855680957 in 7\n",
      "0.0845394177381 in each\n",
      "0.0687055238357 in 68.4\n",
      "0.0683292990001 extended field\n",
      "\n",
      "0.16134682679 shows a\n",
      "0.151615453353 determined to\n",
      "0.140643063116 with a\n",
      "0.133820068706 weeks ,\n",
      "0.126986509522 maximum tolerated\n",
      "0.126986509522 maximum tolerated\n",
      "0.105459451133 for a\n",
      "0.0985203583563 in a\n",
      "0.0967853067483 ) ,\n",
      "0.0906152977495 each .\n",
      "\n",
      "0.287494991058 % )\n",
      "0.28499399413 dead (\n",
      "0.207029846281 mg/m (\n",
      "0.207029846281 mg/m (\n",
      "0.207029846281 mg/m (\n",
      "0.185236008278 months (\n",
      "0.177947396425 % estimated\n",
      "0.176882271517 MTD )\n",
      "0.176882271517 MTD )\n",
      "0.168998656847 % survival\n",
      "\n",
      "0.278151120716 at the\n",
      "0.278151120716 at the\n",
      "0.260959990649 to the\n",
      "0.245412951153 mean of\n",
      "0.235766245067 each of\n",
      "0.212144558797 doses of\n",
      "0.209071892941 determine the\n",
      "0.204747723946 month survival\n",
      "0.201283870173 those deceased\n",
      "0.187103948083 dose of\n",
      "\n",
      "0.141518918045 The 56\n",
      "0.128700297762 was then\n",
      "0.123260488335 analysis of\n",
      "0.11997326642 prospective cohort\n",
      "0.114602246841 determine the\n",
      "0.114288719563 To determine\n",
      "0.112283885893 The MTD\n",
      "0.111655225467 was successfully\n",
      "0.0939708490889 this phase\n",
      "0.0894957972512 previously reported\n",
      "\n",
      "0.256499336784 30-50 mg/m\n",
      "0.232072212208 paclitaxel from\n",
      "0.137180086389 to date\n",
      "0.129458211393 50 %\n",
      "0.0832309598827 to historical\n",
      "0.0831782914287 decrease late\n",
      "0.072705741411 25 months\n",
      "0.0650345491418 40 mg/m\n",
      "0.0650345491418 40 mg/m\n",
      "0.0646668910345 range 25-68\n",
      "\n",
      "0.356209281126 ( maximum\n",
      "0.336605216816 dose reduction\n",
      "0.315074175171 % estimated\n",
      "0.305557173405 selected maximum\n",
      "0.282939218213 the maximum\n",
      "0.239329223206 dose of\n",
      "0.205338984055 A phase\n",
      "0.199166300845 maximum dose\n",
      "0.197065680088 dose (\n",
      "0.197065680088 dose (\n",
      "\n",
      "0.295521837676 those deceased\n",
      "0.271502780338 tolerated dose\n",
      "0.271502780338 tolerated dose\n",
      "0.261926765242 radiation dose\n",
      "0.254253636255 70 mg\n",
      "0.240969758676 than previously\n",
      "0.21821274723 . A\n",
      "0.21821274723 . A\n",
      "0.213598272227 with escalating\n",
      "0.19740939618 ( mean\n",
      "\n",
      "0.334626256876 then evaluated\n",
      "0.328948040822 was seen\n",
      "0.322886306375 was determined\n",
      "0.267040701902 weekly paclitaxel\n",
      "0.252019537949 cycles concurrent\n",
      "0.244491359073 ( maximum\n",
      "0.233391844746 . There\n",
      "0.230149489538 field irradiation\n",
      "0.201519653419 to decrease\n",
      "0.201478953725 from 30-50\n",
      "\n",
      "0.501225709174 four gastrointestinal\n",
      "0.29686403191 toxicity of\n",
      "0.265233753922 toxicity and\n",
      "0.243243612321 toxicity was\n",
      "0.148895434917 the cervix\n",
      "0.0814381486102 administered weekly\n",
      "0.0814381486102 administered weekly\n",
      "0.0716009069752 field pelvic\n",
      "0.0600035759623 reduction is\n",
      "0.0450080266565 doses of\n",
      "\n",
      "0.359675157591 higher than\n",
      "0.311950576981 a larger\n",
      "0.230912167821 is being\n",
      "0.194626856664 of those\n",
      "0.194052749381 a higher\n",
      "0.183641252349 this phase\n",
      "0.178407816018 women with\n",
      "0.151528058302 are dead\n",
      "0.123345640714 being considered\n",
      "0.118678578062 the next\n",
      "\n",
      "0.523697166166 field pelvic\n",
      "0.450259634213 field irradiation\n",
      "0.436295110642 field radiation\n",
      "0.436295110642 field radiation\n",
      "0.370942626317 with extended\n",
      "0.370942626317 with extended\n",
      "0.370942626317 with extended\n",
      "0.370942626317 with extended\n",
      "0.188907507812 the cervix\n",
      "0.160284065836 radiation dose\n",
      "\n",
      "0.752952249047 , twelve\n",
      "0.602297711465 , with\n",
      "0.580340971905 , warrants\n",
      "0.570393661511 48 month\n",
      "0.56974646976 46 months\n",
      "0.55633014744 , and\n",
      "0.55633014744 , and\n",
      "0.55633014744 , and\n",
      "0.520147660206 25 months\n",
      "0.516652414526 ; median\n",
      "\n",
      "0.251669285322 ; median\n",
      "0.244175552108 25 months\n",
      "0.240757041443 ( mean\n",
      "0.232056040449 , twelve\n",
      "0.227916171352 46 months\n",
      "0.217709339881 ( range\n",
      "0.20919858979 range 25-68\n",
      "0.199063404198 48 months\n",
      "0.187994105601 48 month\n",
      "0.184329310123 , and\n",
      "\n",
      "0.0292764358077 cervical cancer\n",
      "0.022549635011 documented para-aortic\n",
      "0.0195041620113 nine weeks\n",
      "0.0181319051406 four gastrointestinal\n",
      "0.0153069521425 eight weeks\n",
      "0.0130361250929 agents were\n",
      "0.0089839409857 node metastases\n",
      "0.0 <MASK> <MASK>\n",
      "0.0 <MASK> <MASK>\n",
      "0.0 <MASK> <MASK>\n",
      "\n",
      "0.293875221643 ( maximum\n",
      "0.281074383127 56 days\n",
      "0.256251050696 ( 2\n",
      "0.256251050696 ( 2\n",
      "0.256251050696 ( 2\n",
      "0.234471489589 ( range\n",
      "0.203209729773 ( MTD\n",
      "0.203209729773 ( MTD\n",
      "0.175262513558 ) in\n",
      "0.169152078217 ( mean\n",
      "\n",
      "0.415296826786 ) .\n",
      "0.415296826786 ) .\n",
      "0.393056710522 each .\n",
      "0.370467876304 nodes .\n",
      "0.369070982131 data .\n",
      "0.357907489318 7 .\n",
      "0.349572509278 cohort .\n",
      "0.335813095145 days .\n",
      "0.315605696859 trial .\n",
      "0.263307004112 ) and\n",
      "\n",
      "0.308911556298 ( mean\n",
      "0.302136574048 % estimated\n",
      "0.260504892829 ( maximum\n",
      "0.243239981441 ; median\n",
      "0.198895190258 ) administered\n",
      "0.173571623973 ) of\n",
      "0.162122152797 . Central\n",
      "0.162061715301 ) are\n",
      "0.161733096723 . Radiation\n",
      "0.151502475956 25-68 ;\n",
      "\n",
      "While primary cisplatin-based intraperitoneal chemotherapy has been shown to favorably impact survival in small-volume residual advanced ovarian cancer, there is a need to develop strategies that improve the effectiveness of this approach. \n",
      "                 A multi-center phase 2 trial was conducted that added intravenous pegylated liposomal doxorubicin (day 8; 30-40 mg/m(2)) to a regimen of intraperitoneal cisplatin (day 2; 75 mg/m(2)) and intravenous (day 1; 135 mg/m(2)) plus intraperitoneal (day 8; 60 mg/m(2)) paclitaxel. Treatment was initially delivered on an every 3-week schedule, but was modified to an every 4-week program due to excessive toxicity. Patients were to receive 6 cycles of this regimen. \n",
      "                 Of 68 patients entering this trial, 63 patients were eligible and evaluable, of whom 39 (62%) completed 6 cycles. Overall, 32 (51%) experienced at least 1 grade 4 or worse toxicity (most commonly hematologic) including 5 treatment-related deaths. Median progression-free survival (PFS) was 25 months (2-year PFS: 52%) and median overall survival 51 months, an outcome similar to previous reports of cisplatin-based intraperitoneal chemotherapy in comparable patient populations. Seventeen patients (27% of all eligible patients) were without evidence of disease recurrence >4 years following entry into the trial. \n",
      "                 Both the overall trial outcome, and specifically the excessively severe systemic toxicity of this regimen would prevent its future development in this exact form. The provocative PFS in a subset of individuals should encourage the development of alternative strategies designed to optimize the delivery of regional therapy in ovarian cancer management.\n",
      "\n",
      "gender Female\n",
      "phase_2 True\n",
      "\n",
      "0.315430502607 development in\n",
      "0.29992455047 future development\n",
      "0.283408528816 development of\n",
      "0.272007531296 its future\n",
      "0.258833139743 the development\n",
      "0.238641946923 would prevent\n",
      "0.22893569012 develop strategies\n",
      "0.228552784052 advanced ovarian\n",
      "0.22610558984 in ovarian\n",
      "0.182303703203 1 grade\n",
      "\n",
      "0.447082414477 , 63\n",
      "0.423429552082 , 32\n",
      "0.354452806207 , an\n",
      "0.351361689754 , and\n",
      "0.343408876144 , but\n",
      "0.323745719529 , of\n",
      "0.296175981353 , there\n",
      "0.243459030815 51 %\n",
      "0.238279366737 52 %\n",
      "0.236887766444 27 %\n",
      "\n",
      "0.528336296736 future development\n",
      "0.482573098304 the development\n",
      "0.345923599804 alternative strategies\n",
      "0.27194023596 develop strategies\n",
      "0.271200195365 to develop\n",
      "0.196911151318 approach .\n",
      "0.196195962509 in small-volume\n",
      "0.183345933916 in a\n",
      "0.174260190636 4-week program\n",
      "0.171855664123 this approach\n",
      "\n",
      "0.215833953577 modified to\n",
      "0.118441719071 similar to\n",
      "0.114749631616 months ,\n",
      "0.103333090433 is a\n",
      "0.0985203583563 in a\n",
      "0.0908798617386 to a\n",
      "0.0866548613084 exact form\n",
      "0.0834685062305 the development\n",
      "0.0789869880607 . A\n",
      "0.0781684635226 comparable patient\n",
      "\n",
      "0.287494991058 % )\n",
      "0.287494991058 % )\n",
      "0.287494991058 % )\n",
      "0.207029846281 mg/m (\n",
      "0.207029846281 mg/m (\n",
      "0.207029846281 mg/m (\n",
      "0.207029846281 mg/m (\n",
      "0.185236008278 months (\n",
      "0.166196133584 patients (\n",
      "0.163835421743 severe systemic\n",
      "\n",
      "0.187465527695 outcome similar\n",
      "0.180544637467 Both the\n",
      "0.151281684336 least 1\n",
      "0.146922739254 were to\n",
      "0.139613819246 day 1\n",
      "0.138526810208 % of\n",
      "0.137973190671 . The\n",
      "0.131842702427 every 4-week\n",
      "0.125834386354 day 2\n",
      "0.123779419681 specifically the\n",
      "\n",
      "0.158085506223 evidence of\n",
      "0.15551291148 was initially\n",
      "0.144387180739 this trial\n",
      "0.122443762082 conducted that\n",
      "0.118507537846 this approach\n",
      "0.113897152379 The provocative\n",
      "0.103662012005 was conducted\n",
      "0.102698569061 While primary\n",
      "0.0991856650671 to previous\n",
      "0.092126922571 this regimen\n",
      "\n",
      "0.178640932204 30-40 mg/m\n",
      "0.0850245524543 to favorably\n",
      "0.072705741411 25 months\n",
      "0.0663448065638 60 mg/m\n",
      "0.0633080465996 to receive\n",
      "0.0544800068473 75 mg/m\n",
      "0.0522096015422 to excessive\n",
      "0.0496016498291 to previous\n",
      "0.0446561525339 excessively severe\n",
      "0.0342244792769 to an\n",
      "\n",
      "0.174644274348 multi-center phase\n",
      "0.123399676466 30-40 mg/m\n",
      "0.107708682839 to optimize\n",
      "0.0887684631019 to excessive\n",
      "0.0865262853408 to an\n",
      "0.0854882055614 overall trial\n",
      "0.0802867070139 at least\n",
      "0.0773448395397 treatment-related deaths\n",
      "0.0555929352571 median overall\n",
      "0.0529360350834 delivered on\n",
      "\n",
      "0.21821274723 . A\n",
      "0.168582577173 27 %\n",
      "0.167206836247 every 4-week\n",
      "0.164206324684 ( day\n",
      "0.164206324684 ( day\n",
      "0.164206324684 ( day\n",
      "0.164206324684 ( day\n",
      "0.161132758745 ) plus\n",
      "0.157294299937 62 %\n",
      "0.154507530087 ( PFS\n",
      "\n",
      "0.504412817219 intraperitoneal cisplatin\n",
      "0.405500734835 intraperitoneal chemotherapy\n",
      "0.405500734835 intraperitoneal chemotherapy\n",
      "0.349742113443 intraperitoneal (\n",
      "0.319404921952 intravenous pegylated\n",
      "0.292122726798 intravenous (\n",
      "0.232970982562 in comparable\n",
      "0.225677576357 3-week schedule\n",
      "0.204647238805 liposomal doxorubicin\n",
      "0.197985487775 plus intraperitoneal\n",
      "\n",
      "0.516804865194 added intravenous\n",
      "0.396823979467 conducted that\n",
      "0.337346163468 toxicity (\n",
      "0.29686403191 toxicity of\n",
      "0.282906986906 toxicity .\n",
      "0.232625057053 strategies that\n",
      "0.13384790305 entering this\n",
      "0.121244064267 in ovarian\n",
      "0.10953756222 plus intraperitoneal\n",
      "0.102230799404 into the\n",
      "\n",
      "0.2782385222 ( most\n",
      "0.266886059677 the excessively\n",
      "0.229859263323 to develop\n",
      "0.210802032353 this approach\n",
      "0.197750937117 to receive\n",
      "0.195993303382 excessively severe\n",
      "0.1868352649 develop strategies\n",
      "0.172820559586 4 or\n",
      "0.157102119883 exact form\n",
      "0.154444851619 most commonly\n",
      "\n",
      "0.263899026693 the excessively\n",
      "0.193683569003 phase 2\n",
      "0.170827892387 severe systemic\n",
      "0.159538813737 at least\n",
      "0.157767733161 advanced ovarian\n",
      "0.147661598176 a regimen\n",
      "0.14757307605 multi-center phase\n",
      "0.145373148803 of alternative\n",
      "0.138688945753 to excessive\n",
      "0.133364071032 residual advanced\n",
      "\n",
      "0.69377254086 4 years\n",
      "0.692489806278 , 63\n",
      "0.679843287963 , 32\n",
      "0.637017087432 , there\n",
      "0.623514627011 , of\n",
      "0.589737222571 , an\n",
      "0.572349483207 51 months\n",
      "0.571141164163 , but\n",
      "0.55633014744 , and\n",
      "0.520147660206 25 months\n",
      "\n",
      "0.335732583095 4 years\n",
      "0.271571830463 , 63\n",
      "0.252522350553 , there\n",
      "0.244175552108 25 months\n",
      "0.243945079876 , 32\n",
      "0.231147718086 , of\n",
      "0.215675679109 51 months\n",
      "0.201241079536 and median\n",
      "0.190169946687 ( 2-year\n",
      "0.184329310123 , and\n",
      "\n",
      "0.21808267094 to previous\n",
      "0.128870376085 reports of\n",
      "0.0950792265479 ovarian cancer\n",
      "0.0950792265479 ovarian cancer\n",
      "0.0903057231189 previous reports\n",
      "0.0550186456088 added intravenous\n",
      "0.0435438586237 of intraperitoneal\n",
      "0.028434937707 The provocative\n",
      "0.0281942092394 following entry\n",
      "0.0278644784246 While primary\n",
      "\n",
      "0.490378661486 ( day\n",
      "0.490378661486 ( day\n",
      "0.490378661486 ( day\n",
      "0.490378661486 ( day\n",
      "0.256251050696 ( 2\n",
      "0.256251050696 ( 2\n",
      "0.256251050696 ( 2\n",
      "0.256251050696 ( 2\n",
      "0.199108926605 4 or\n",
      "0.16528457968 1 grade\n",
      "\n",
      "0.418522408168 populations .\n",
      "0.341645619641 deaths .\n",
      "0.331507783701 cycles .\n",
      "0.315605696859 trial .\n",
      "0.314631614794 approach .\n",
      "0.308729812926 4 or\n",
      "0.297471328785 form .\n",
      "0.285407274822 paclitaxel .\n",
      "0.263307004112 ) and\n",
      "0.263307004112 ) and\n",
      "\n",
      "0.30197838968 ; 135\n",
      "0.264738739525 ; 30-40\n",
      "0.242766111387 , there\n",
      "0.223215158517 ; 60\n",
      "0.188446315854 ) to\n",
      "0.170925294261 ) were\n",
      "0.163363528144 , an\n",
      "0.162409538729 ) plus\n",
      "0.154472746519 ) was\n",
      "0.151872492755 8 ;\n",
      "\n",
      "Long-term androgen suppression plus radiotherapy (AS+RT) is standard treatment of high-risk prostate cancer. A randomized trial, Radiation Therapy Oncology Group trial 9902, was undertaken to determine whether adjuvant chemotherapy with paclitaxel, estramustine, and etoposide (TEE) plus AS+RT would improve disease outcomes with acceptable toxicity. \n",
      "                 High-risk (prostate-specific antigen 20-100 ng/mL and Gleason score >or=7; or Stage T2 or greater, Gleason score 8, prostate-specific antigen level <100 ng/mL) nonmetastatic prostate cancer patients were randomized to AS+RT (Arm 1) vs. AS+RT plus four cycles of TEE (Arm 2). TEE was delivered 4 weeks after RT. AS continued for 2 years for both treatment arms. RT began after 8 weeks of AS began. \n",
      "                 The Radiation Therapy Oncology Group 9902 trial opened January 11, 2000. Excess thromboembolic toxicity was noted, leading to study closure October 4, 2004. A total of 397 patients were accrued, and the data for 381 were analyzable. An acute and long-term toxicity analysis was performed. The worst overall toxicities during treatment were increased for Arm 2. Of the 192 patients, 136 (71%) on Arm 2 had RTOG Grade 3 or greater toxicity compared with 70 (37%) of 189 patients on Arm 1. Statistically significant increases in hematologic toxicity (p < 0.0001) and gastrointestinal toxicity (p = 0.017) but not genitourinary toxicity (p = 0.07) were noted during treatment. Two Grade 5 complications related to neutropenic infection occurred in Arm 2. Three cases of myelodysplasia/acute myelogenous leukemia were noted in Arm 2. At 2 and 3 years after therapy completion, excess long-term toxicity was not observed in Arm 2. \n",
      "                 TEE was associated with significantly increased toxicity during treatment. The toxicity profiles did not differ at 2 and 3 years after therapy. Toxicity is an important consideration in the design of trials using adjuvant chemotherapy for prostate cancer.\n",
      "\n",
      "gender Male\n",
      "phase_2 False\n",
      "\n",
      "0.327538122198 and Gleason\n",
      "0.265655915721 , Gleason\n",
      "0.248469563938 ) nonmetastatic\n",
      "0.228920109384 during treatment\n",
      "0.228920109384 during treatment\n",
      "0.228920109384 during treatment\n",
      "0.220965022485 of high-risk\n",
      "0.214128803745 , leading\n",
      "0.212776417361 improve disease\n",
      "0.18893180061 . High-risk\n",
      "\n",
      "0.401383025141 , 2004\n",
      "0.394678817655 , 2000\n",
      "0.366178598814 , leading\n",
      "0.35994686818 , was\n",
      "0.351361689754 , and\n",
      "0.351361689754 , and\n",
      "0.329204437539 , excess\n",
      "0.323769084172 , 136\n",
      "0.29986890454 , estramustine\n",
      "0.298355909345 , prostate-specific\n",
      "\n",
      "0.183823970708 in Arm\n",
      "0.183823970708 in Arm\n",
      "0.183823970708 in Arm\n",
      "0.163747745397 AS began\n",
      "0.154903469503 important consideration\n",
      "0.154893338484 Radiation Therapy\n",
      "0.154893338484 Radiation Therapy\n",
      "0.145599154597 the design\n",
      "0.12456916414 in the\n",
      "0.119471849502 standard treatment\n",
      "\n",
      "0.256997915879 0.07 )\n",
      "0.150115952189 0.017 )\n",
      "0.14629444694 greater ,\n",
      "0.128456673771 score 8\n",
      "0.113423345394 ng/mL and\n",
      "0.108094641855 completion ,\n",
      "0.105615853129 = 0.017\n",
      "0.105312592795 = 0.07\n",
      "0.103838828371 p =\n",
      "0.103838828371 p =\n",
      "\n",
      "0.346822459757 0.07 )\n",
      "0.287494991058 % )\n",
      "0.287494991058 % )\n",
      "0.254664774445 ; or\n",
      "0.238716353889 High-risk (\n",
      "0.220989359543 ng/mL )\n",
      "0.21851862176 TEE (\n",
      "0.178391341141 TEE )\n",
      "0.177766809306 = 0.017\n",
      "0.168280192806 ng/mL and\n",
      "\n",
      "0.259820919041 weeks of\n",
      "0.24975765558 level <\n",
      "0.240601020879 significantly increased\n",
      "0.234524601438 score 8\n",
      "0.233976773274 score >\n",
      "0.201023754613 TEE was\n",
      "0.201023754613 TEE was\n",
      "0.196401824686 were increased\n",
      "0.186817870116 and the\n",
      "0.185670799874 ng/mL and\n",
      "\n",
      "0.693818427161 study closure\n",
      "0.200742288386 undertaken to\n",
      "0.152937104928 of myelodysplasia/acute\n",
      "0.150504854175 AS continued\n",
      "0.139551075383 determine whether\n",
      "0.1359272979 was undertaken\n",
      "0.134388461829 to neutropenic\n",
      "0.131190978092 whether adjuvant\n",
      "0.126147649797 trial opened\n",
      "0.107263644925 9902 trial\n",
      "\n",
      "0.227436981012 20-100 ng/mL\n",
      "0.146556793675 100 ng/mL\n",
      "0.0979027455663 to study\n",
      "0.0355150860963 AS+RT would\n",
      "0.0318333016742 > or=7\n",
      "0.0313017580117 opened January\n",
      "0.0302302430675 increases in\n",
      "0.0302096941411 an important\n",
      "0.0257081189624 AS began\n",
      "0.0237616724417 were accrued\n",
      "\n",
      "0.130009305726 antigen 20-100\n",
      "0.111118543746 to determine\n",
      "0.0983409298103 antigen level\n",
      "0.0968969602731 infection occurred\n",
      "0.0861439764157 toxicity during\n",
      "0.0827954969171 significant increases\n",
      "0.0757459575826 significantly increased\n",
      "0.0723058473525 toxicity analysis\n",
      "0.070324416649 20-100 ng/mL\n",
      "0.0700362551649 A total\n",
      "\n",
      "0.401422870891 Group trial\n",
      "0.401282868818 Group 9902\n",
      "0.280774121557 vs. AS+RT\n",
      "0.244818495619 or greater\n",
      "0.244818495619 or greater\n",
      "0.235179057995 compared with\n",
      "0.231059551865 ( AS+RT\n",
      "0.21821274723 . A\n",
      "0.21821274723 . A\n",
      "0.212881546575 Gleason score\n",
      "\n",
      "0.617722324255 not observed\n",
      "0.450109095683 during treatment\n",
      "0.450109095683 during treatment\n",
      "0.450109095683 during treatment\n",
      "0.436296493082 were noted\n",
      "0.436296493082 were noted\n",
      "0.396262561256 was noted\n",
      "0.325305080671 after RT\n",
      "0.32307736618 were increased\n",
      "0.316496219551 significant increases\n",
      "\n",
      "0.434538873297 and gastrointestinal\n",
      "0.337346163468 toxicity (\n",
      "0.337346163468 toxicity (\n",
      "0.337346163468 toxicity (\n",
      "0.335629638399 Toxicity is\n",
      "0.333280725547 toxicity profiles\n",
      "0.328683207458 toxicity during\n",
      "0.282906986906 toxicity .\n",
      "0.268468846934 toxicity analysis\n",
      "0.248428001592 toxicity compared\n",
      "\n",
      "0.266448571691 or greater\n",
      "0.266448571691 or greater\n",
      "0.209922475797 outcomes with\n",
      "0.179702690269 T2 or\n",
      "0.169384507084 3 or\n",
      "0.162899181645 with significantly\n",
      "0.150434282796 2 had\n",
      "0.145613244785 infection occurred\n",
      "0.118607038622 AS continued\n",
      "0.117584659846 differ at\n",
      "\n",
      "0.142118867826 four cycles\n",
      "0.133846430176 with acceptable\n",
      "0.116874098709 on Arm\n",
      "0.116874098709 on Arm\n",
      "0.104150321233 trial opened\n",
      "0.0973237477554 AS began\n",
      "0.0923618464126 opened January\n",
      "0.0920835724331 October 4\n",
      "0.0908939585281 to neutropenic\n",
      "0.0864511479007 toxicity during\n",
      "\n",
      "0.813276746571 , 2000\n",
      "0.783296007384 , 2004\n",
      "0.711286362473 3 years\n",
      "0.711286362473 3 years\n",
      "0.701683935487 2 years\n",
      "0.694503720037 , was\n",
      "0.639154989772 , 136\n",
      "0.634387141725 , prostate-specific\n",
      "0.587867648485 , estramustine\n",
      "0.579447508698 , Gleason\n",
      "\n",
      "0.332929525001 3 years\n",
      "0.332929525001 3 years\n",
      "0.317044369577 2 years\n",
      "0.291145832317 , Gleason\n",
      "0.271843391371 , prostate-specific\n",
      "0.260966572583 , was\n",
      "0.246102815968 , 2000\n",
      "0.23664234266 , 2004\n",
      "0.20625048237 , 136\n",
      "0.186011642822 , excess\n",
      "\n",
      "0.247077646658 suppression plus\n",
      "0.219140202749 androgen suppression\n",
      "0.0679726557415 not differ\n",
      "0.0635168816537 20-100 ng/mL\n",
      "0.0454151035387 profiles did\n",
      "0.0426200229311 antigen level\n",
      "0.0388373902847 antigen 20-100\n",
      "0.036044108958 Three cases\n",
      "0.0263302836244 leukemia were\n",
      "0.0247442337085 myelogenous leukemia\n",
      "\n",
      "0.277068174871 ( TEE\n",
      "0.253367080981 4 weeks\n",
      "0.229703963499 ( Arm\n",
      "0.229703963499 ( Arm\n",
      "0.215585302392 8 weeks\n",
      "0.209042593486 1 .\n",
      "0.206584924747 ( p\n",
      "0.206584924747 ( p\n",
      "0.206584924747 ( p\n",
      "0.198533143287 ) on\n",
      "\n",
      "0.419448348978 2000 .\n",
      "0.416946982863 2 .\n",
      "0.416946982863 2 .\n",
      "0.416946982863 2 .\n",
      "0.416946982863 2 .\n",
      "0.415296826786 ) .\n",
      "0.411740218445 1 .\n",
      "0.404869567708 2004 .\n",
      "0.389944467426 began .\n",
      "0.359874737762 arms .\n",
      "\n",
      "0.921929861757 = 0.07\n",
      "0.501025054859 = 0.017\n",
      "0.399042884583 ) vs.\n",
      "0.378015366366 p =\n",
      "0.378015366366 p =\n",
      "0.362787014127 ( p\n",
      "0.362787014127 ( p\n",
      "0.362787014127 ( p\n",
      "0.279280767264 , excess\n",
      "0.246418344008 , Radiation\n",
      "\n"
     ]
    }
   ],
   "source": [
    "filters = model.nodes['conv'].W.eval()\n",
    "filters = np.squeeze(filters)\n",
    "filters = [filter.T for filter in filters]\n",
    "\n",
    "def activation_generator(filter, abstract):\n",
    "    for w1, w2 in zip(abstract, abstract[1:]):\n",
    "        yield np.sum(embeddings[[w1, w2]] * filter), (w1, w2)\n",
    "        \n",
    "def activations_generator(filters, abstract):\n",
    "    for filter in filters:\n",
    "        yield list(activation_generator(filter, abstract))\n",
    "        \n",
    "def show_activations(filters, abstract):\n",
    "    activations = list(activations_generator(filters, abstract))\n",
    "\n",
    "    for activation in activations:\n",
    "        for score, (w1, w2) in sorted(activation, reverse=True)[:10]:\n",
    "            print score, idx2word[w1], idx2word[w2]\n",
    "\n",
    "        print\n",
    "\n",
    "for idx in [0, 2, 7, 9, 10]:\n",
    "    print abstracts[idx]\n",
    "    print\n",
    "    for label, symbol in zip(labels, ys[:, idx]):\n",
    "        print label, class_names[label][symbol]\n",
    "    print\n",
    "    \n",
    "    show_activations(filters, abstracts_padded[idx])"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 2",
   "language": "python",
   "name": "python2"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.11"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 0
}
